AlphaProteo designs high-affinity protein binders, including the first AI-designed VEGF-A binder
DeepMind's AlphaProteo generated protein binders for 7 targets with 9–88% experimental success rates (88% for BHRF1) and 3–300× better affinities than prior methods. It produced the first successful AI-designed binder for VEGF-A.
Key facts
- Experimental binding success 9–88% across 7 targets
- Affinities 3–300× better than the best previous methods on several targets
- Technical report, not peer-reviewed at announcement
Science result
- Field
- biology / protein design
- Problem
- Designing high-affinity binders to disease targets
- Result
- Lab-validated de novo binders for 7 targets, including VEGF-A, at high success rates.
- AI system
- AlphaProteo
- Human role
- Human-designed system; lab testing by collaborators
- Verification
- Lab-validated; technical report (not peer-reviewed at release)
- Status
- confirmed
What happened
DeepMind released a binder-design system and reported wet-lab results from partner labs.
Why it matters
High one-shot success rates cut the months of screening normally needed to find a binder.
Changelog
- 2026-09-29: created
Related events
Sources (2)
- officialDeepMind: AlphaProteo generates novel proteins for biology and health research
- pressMobiHealthNews: Google DeepMind unveils AlphaProteo
id: 2024-09-05-alphaproteo · updated 2026-09-29 · open in the interactive timeline